Abbott and Novo Nordisk have begun a non-exclusive partnership to provide integrated digital solutions for patients with diabetes requiring insulin.
The collaboration enables insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with Abbott’s Free Style Libre products.
The FreeStyle Libre system reads glucose levels through sensors worn on the back of the upper arm thereby eliminating the former necessity of routine finger pricks. The product essentially allows patients and carers to capture and view real-time glucose levels, as well as their eight-hour glucose history and how their glucose levels are fluctuating on a smartphone.
Integrating the sensor and digital health tools ultimately enables healthcare professionals, caregivers and patients to view glucose and insulin data helping them to make better treatment decisions as well as providing. more meaningful and productive conversation about health outcomes.
Anders Dyhr Toft, corporate Vice President of Commercial Innovation at Novo Nordisk, said: “Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors.
“Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient’s individual diabetes management and can help people with diabetes feel more confident in their treatment.”
Jared Watskin, senior Vice President of Diabetes Care at Abbott, added: “By enabling insulin dosing data from Novo Nordisk’s connected pens to be shared with our digital health tools, we’ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life.”